Canada markets closed

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
3.1200-0.0100 (-0.32%)
At close: 04:00PM EDT
3.1300 +0.01 (+0.32%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.1300
Open3.1200
Bid3.1200 x 27000
Ask3.1500 x 38500
Day's Range3.0900 - 3.4100
52 Week Range2.0900 - 15.8640
Volume28,130,986
Avg. Volume25,263,595
Market Cap5.851B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports

    Public-private partnership to enable the development of innovative, sustainable infrastructure designed to set the global standard for travel biosecurityBOSTON and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XpresSpa Group, Inc. (Nasdaq: XSPA) announced they will continue to support the Centers for Disease Control and Prevention’s (CDC’s) traveler-based SARS-CoV-2 genomic surveillance program through a new contract awarded August 12, 2022. The partnership is expec

  • GlobeNewswire

    Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

    TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity ta

  • Business Wire

    Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

    SOUTH SAN FRANCISCO, Calif. & BOSTON, April 05, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem. The four-year agreement in